Research programme: tuberculosis therapies - ChemDiv/Chemical Diversity Research Institute

Drug Profile

Research programme: tuberculosis therapies - ChemDiv/Chemical Diversity Research Institute

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemDiv; Chemical Diversity Research Institute; Novartis Institute for Tropical Diseases
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in Russia
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in Singapore
  • 06 Oct 2011 Chemical Diversity Research Institute enters collaboration and License Option Agreement with Novartis Institute for Tropical Diseases for this research programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top